Act Now: SLNO Investors Urged to Secure Counsel!

Company Overview & Recent Developments

Soleno Therapeutics (NASDAQ: SLNO) is a biotech company focused on rare diseases, best known for developing VYKAT™ XR (diazoxide choline extended-release tablets) to treat hyperphagia in Prader-Willi syndrome (PWS) (www.sec.gov) (investors.soleno.life). In March 2025, Soleno achieved a major milestone when the FDA approved VYKAT XR – the first-ever therapy addressing the hallmark insatiable appetite of PWS (investors.soleno.life). Commercial launch began in April 2025, and initial uptake was robust: by Q2 2025 the company had received 646 patient start forms from 295 unique prescribers (investors.soleno.life). This translated into $32.7 million in Q2 2025 revenue, Soleno’s first quarter of sales (investors.soleno.life). Revenues nearly doubled to $66.0 million in Q3 2025 as more patients initiated therapy (www.sec.gov), underscoring strong early demand.

However, mid-August 2025 brought serious turbulence. Activist short-seller Scorpion Capital published a highly critical report on August 15, 2025, alleging alarming safety issues with VYKAT XR (ng.investing.com). The report cited a “rapid pile-up of reports of children hospitalized for potential heart failure” shortly after starting VYKAT XR (ng.investing.com). Scorpion warned the drug might even face withdrawal from the market or a plunge in new prescriptions (ng.investing.com). The same report lambasted Soleno as a “one-trick pony” with no meaningful pipeline or assets beyond VYKAT XR (www.prnewswire.com). Notably, Scorpion highlighted that Soleno’s sole drug is essentially an “inferior tablet version of a half-century old suspension” and pointed out that the core patent for DCCR (diazoxide choline) expires in 2026 (www.prnewswire.com) – implying limited long-term exclusivity. The short-seller also questioned Soleno’s launch metrics as “hocus-pocus,” suggesting that an unusually large portion of initial prescriptions came via a single influential physician (the lead investigator on Soleno’s trials) (www.prnewswire.com). Even more troubling, Scorpion alleged irregularities in that physician’s co-authored trial data, hinting at potential data integrity red flags in Soleno’s clinical results and FDA submissions (www.prnewswire.com).

The market reacted swiftly. SLNO stock plunged ~12% over two trading days on the heels of Scorpion’s report (portal.sina.com.hk). In the wake of this drop, multiple shareholder rights law firms stepped forward. For example, Rosen Law Firm issued notices in September 2025 “encourag[ing] investors who have suffered losses in Soleno to contact counsel” as it investigates whether Soleno misled investors about VYKAT XR’s safety or prospects (www.prnewswire.com) (www.prnewswire.com). Similarly, Hagens Berman announced an investigation focused on the propriety of Soleno’s statements regarding VYKAT XR’s safety and commercial outlook (www.prnewswire.com). This unusual confluence of a short-seller attack and ensuing legal investigations has created an atmosphere of urgency – hence the rallying cry for SLNO investors to “act now” and consider securing counsel.

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

Dividend Policy & Cash Flows (AFFO/FFO)

Soleno has never paid a dividend, and it does not expect to pay one in the foreseeable future (www.sec.gov). As a development-stage biotech, the company has historically reinvested any capital into R&D and now commercialization, rather than returning cash to shareholders. Management explicitly states that all earnings, if any, will be retained to fund operations and growth, with no plans to declare cash dividends on common stock (www.sec.gov). This policy is unsurprising given that Soleno only just began generating revenue in 2025 and has not achieved sustained profitability. In fact, the company used cash in operating activities (burning about $12.6 million in Q2 2025) as it ramps up its commercial launch (investors.soleno.life). Traditional REIT metrics like FFO/AFFO don’t apply here – Soleno’s focus is on reaching positive operating cash flow through VYKAT XR sales. Until recurring profits materialize, any “yield” for investors must come from stock price appreciation, not dividends (www.sec.gov). Investors in SLNO should therefore be comfortable with a growth-oriented, non-dividend stock, where the value hinges on successful drug uptake rather than income generation.

Leverage & Debt Maturities

Despite its recent challenges, Soleno’s balance sheet is relatively strong after a series of financings. The company has primarily funded operations via equity raises and a venture debt facility, rather than excessive leverage. In December 2024, Soleno entered a loan and security agreement with Oxford Finance LLC for up to $200 million (www.sec.gov) (www.sec.gov). An initial tranche (reportedly around $100 million) was drawn, and an additional $100 million was structured into contingent tranches: $50 million and $25 million contingent on FDA approval of DCCR (now VYKAT XR) and a commercial milestone, plus a final $25 million available with mutual consent (www.sec.gov). The FDA approval in March 2025 likely unlocked one or more of these tranches, though it’s unclear how much Soleno has opted to draw so far. Importantly, the Oxford loan carries an interest-only period of 48 months and a total term of 60 months (five years), extendable by 12 months if certain milestones are met by September 30, 2026 (www.sec.gov). In practical terms, this means principal repayment won’t be due until late 2029 (or late 2030 with extension), giving Soleno a multi-year runway before the debt matures. The interest rate is floating at one-month SOFR + 5.50%, which currently equates to roughly ~10% annually (www.sec.gov).

Crucially, Soleno augmented its cash reserves with a major equity raise in mid-2025. In July, just after the FDA approval, the company issued ~2.35 million new shares at $85 each – a $200 million public offering (increased to $230 million with underwriters’ options) (investors.soleno.life). This capital infusion brought Soleno’s cash balance to about $294 million as of Q2 2025 (excluding the July raise) (investors.soleno.life), which pro-forma would exceed $500 million when including the offering proceeds. Even after funding the VYKAT XR launch ramp-up, Soleno holds a substantial net cash position. With roughly ~$100–125 million in venture debt and well over $300 million in cash on hand post-offering, the company is minimally leveraged in net terms. There are debt covenants (typical restrictions on further liens, new debt, mergers, etc.) in the Oxford agreement (www.sec.gov), but Soleno’s war chest from the equity raise provides significant flexibility to meet its obligations and invest in growth. In summary, debt maturities are a distant concern – the bulk of principal repayment is years away – and the current leverage is modest, especially relative to the cash on the balance sheet.

Coverage & Liquidity

From a coverage perspective, Soleno’s ability to service its debt and other fixed obligations hinges on its cash reserves, as the company is not yet consistently generating positive earnings. Traditional interest coverage ratios (EBITDA/interest) are currently not meaningful since Soleno only turned a net profit in one recent quarter and remains net-loss making over the first nine months of 2025 (www.sec.gov). In the nine months ended Sept 30, 2025, Soleno recorded an overall net loss of ~$22.5 million despite the initial revenue ramp (www.sec.gov). This implies that operating income wasn’t sufficient to cover all expenses (including interest) over that period. However, the Q3 2025 profitability blip – a $26 million net income in that quarter alone (www.sec.gov) – suggests that if VYKAT XR’s sales trajectory continues upward, Soleno could begin covering interest costs from operating profit going forward. For now, though, interest coverage is coming from the balance sheet: interest payments on the Oxford loan (estimated at ~$10 million annually) are comfortably funded out of Soleno’s large cash reserve.

Liquidity is not an issue in the near term. With hundreds of millions in cash available, Soleno can easily pay its interest (and eventually principal) for the foreseeable future. The Oxford debt is interest-only for the next 3–4 years, allowing Soleno to preserve cash while it scales revenue (www.sec.gov). Additionally, the company could likely pay down debt early if desired; but given the interest-only structure and no imminent maturities, management is focusing cash on commercialization and potentially new opportunities. It’s worth noting that Soleno’s cash burn – the rate at which it uses cash for R&D and SG&A – will be a key factor in future coverage. In Q2 2025, operating cash burn was ~$12.6 million (investors.soleno.life); as sales grow and one-time launch costs taper, this burn may decline or flip to positive cash flow. For now, coverage ratios remain weak on an income basis, but liquidity is strong. Investors should monitor how quickly Soleno’s burgeoning revenue can catch up to its expense base. The company itself cautions that although it has begun to generate product revenue, it “may not maintain profitability” consistently (www.sec.gov) – so cash coverage of obligations could still be necessary if any earnings setbacks occur.

Valuation & Comparables

Valuing SLNO is challenging, as with many emerging biotechs, because traditional metrics like P/E or P/FFO are not applicable (earnings are minimal or negative). Instead, investors look at metrics like revenue multiples and pipeline potential. Following the Q3 2025 results, Soleno’s run-rate revenue can be extrapolated to roughly $130–150 million annually (given $98.7 M in net sales for the first nine months) (www.sec.gov). With the stock recently trading around the mid-$40s per share, Soleno’s market capitalization is in the ~$1.8–$2.0 billion range (roughly 48–49 million shares outstanding post-offering). This implies a Price/Sales multiple on the order of ~12–15× current annualized sales. Such a multiple is relatively rich, reflecting the expectation of steep growth in PWS treatment adoption and high gross margins typical of rare-disease drugs. For context, other orphan-drug biotechs with newly launched products often trade at high P/S ratios (10–20×) in early years, especially if they have monopoly status in their indication. Soleno does have the first-mover advantage in PWS, which can command a premium valuation.

However, the market’s confidence in those lofty expectations has been shaken by recent events. Prior to the short-seller controversy, SLNO’s stock soared as high as the $70–$80+ range (the July 2025 offering priced at $85/share was actually oversubscribed) (investors.soleno.life). Some analysts were extremely bullish: as of late summer 2025, the consensus price target was about $118.45 – implying over 100% upside from a mid-$50s stock price at that time (financhill.com). In fact, eight Wall Street analysts had an average target more than double the then-current price (financhill.com). These targets likely assumed VYKAT XR would penetrate the majority of PWS patients and perhaps expand into new markets (e.g. pediatric use globally, or other indications like Smith-Magenis syndrome in the future). Bulls also point to Soleno’s significant cash (over $500 M post-raise) which could be deployed for pipeline expansion or acquisitions to fuel growth (investors.soleno.life). From a relative valuation angle, if VYKAT XR reaches peak sales in the hundreds of millions annually, a $2 B market cap might look reasonable or even cheap (typical biotech takeout multiples for successful orphans can be 4–6× peak sales).

On the other hand, bearish views (such as Scorpion’s) argue the stock is wildly overpriced if the drug’s prospects are imperiled. If, for instance, safety concerns curtail VYKAT’s use or if it were withdrawn, Soleno’s revenue could vanish – making any revenue multiple meaningless. Moreover, with patent protection lapsing by 2026 on the core formulation (www.prnewswire.com), Soleno may rely on orphan drug exclusivity (7-year U.S. market exclusivity from approval) as its main moat. Any hint that competition or generics could emerge after that window could compress the valuation dramatically. In summary, SLNO’s valuation carries a wide range of outcomes. It straddles the line between a high-growth rare disease play (with valuations to match) and a binary risky biotech (vulnerable to collapse if its one product fails). The stark contrast between Wall Street’s ~$118 bullish target and the short-seller’s essentially zero valuation thesis highlights this uncertainty. Investors should weigh the upside of continued commercial success versus the downside of potential clinical or commercial failure when assessing Soleno’s valuation.

Risks & Red Flags

Soleno Therapeutics faces a number of key risks and red flags, which have been amplified by the recent short report and ensuing scrutiny. Below are the major concerns investors should consider:

– Product Safety Concerns: The most urgent risk is the safety profile of VYKAT XR in real-world use. Scorpion Capital’s investigation noted a “rapid pile-up” of serious adverse events – specifically potential heart failure in children shortly after starting the drug (ng.investing.com). While these reports are unconfirmed, even a perception of severe side effects could trigger regulatory action or drastically reduce physician willingness to prescribe VYKAT XR. The short report warned that the drug might be at risk of withdrawal from the market or sharply declining new prescriptions if safety issues persist (ng.investing.com). Soleno’s management has since acknowledged that spontaneous FDA adverse event reports (FAERS) are being monitored daily and cautioned that such reports can be misinterpreted without context (www.sec.gov). Nevertheless, this is a critical risk – any confirmed pattern of cardiotoxicity or other serious harm would be devastating for patients and for Soleno’s viability.

– “One-Trick Pony” Dependence: Soleno currently derives 100% of its revenue from VYKAT XR, with no other commercial products or significant pipeline candidates to diversify risk. The short report emphasized that Soleno lacks “meaningful assets [or] pipeline” beyond this one drug (www.prnewswire.com). This means the company’s fate is entirely tied to VYKAT’s success in PWS (and potentially a few niche expansions). If VYKAT XR were to fail commercially or be pulled, Soleno has no alternative revenue streams – a classic single-product risk. Even management in its filings concedes that Soleno has “just begun to generate revenue and may not maintain profitability” if obstacles arise (www.sec.gov). The company has patent applications related to uses of diazoxide choline in PWS and a similar disorder (Smith-Magenis Syndrome) (www.sec.gov), but those are longer-term and do not negate the immediate concentration of risk. Until Soleno acquires or develops another therapy, it remains an all-or-nothing bet on VYKAT XR.

– Intellectual Property & Exclusivity: A related red flag is the limited patent life on Soleno’s flagship drug. According to the short-seller (and confirmed by Soleno’s filings), the 20-year term on key U.S. patents expires between 2025 and 2035 (www.sec.gov), with the core patent reportedly expiring in 2026 (www.prnewswire.com). While VYKAT XR likely has Orphan Drug exclusivity in the U.S. (7 years from approval, i.e. until 2032) protecting it from direct competition, the patent expiry could allow generics after that period or even invites challenges to Soleno’s formulation patents. The short report’s characterization of VYKAT as essentially a modified version of an older drug (diazoxide, a half-century-old compound) further raises concern that competitors might formulate around the patents (www.prnewswire.com). If Soleno cannot extend its IP protection (through new patents or reformulations) or build a pipeline of follow-on products, the long-term sustainability of its revenue stream is questionable. The company itself warns that its “patent rights may prove an inadequate barrier to competition” and that any loss of exclusivity could greatly harm its business (www.sec.gov).

– Questionable Launch Metrics: The integrity of Soleno’s commercial rollout has been called into question. Scorpion Capital alleged that Soleno’s impressive early prescription numbers might be inflated by an overreliance on a single physician championing the drug (www.prnewswire.com). Specifically, a prominent PWS expert in Gainesville, FL (who was the lead investigator in trials) was suggested to be an “invisible hand fueling initial start forms” (www.prnewswire.com). If true, this could mean the breadth of prescriber adoption is narrower than reported (i.e., one enthusiastic doctor accounting for a disproportionate share of prescriptions). Additionally, Scorpion scrutinized some of that physician’s co-authored research on DCCR, claiming “irregularities” in data that hint at potential issues with scientific rigor (www.prnewswire.com). These allegations cast a shadow on the quality of Soleno’s clinical data and launch figures. Even if Soleno disputes these claims, investors must consider the risk that initial demand was front-loaded or artificially boosted, and that sustaining genuine growth might be harder if other physicians are more cautious. The credibility of management’s communications is under the microscope as well – indeed, Hagens Berman is investigating whether Soleno made misleading statements about the level of support and demand for VYKAT XR (www.prnewswire.com).

– Legal and Reputational Risks: The fallout from the short report has led to at least two law firms (Rosen and Hagens Berman) seeking to represent shareholders in potential actions (www.prnewswire.com) (www.prnewswire.com). While no lawsuit has been confirmed yet (as of this report), the ongoing investigations pose a risk of a future securities class action. Even if Soleno ultimately prevails (or settles) without admitting wrongdoing, the process could divert management’s attention and add legal expenses. Moreover, the very public nature of these accusations – magnified by GlobeNewswire releases urging investors to “act now” and contact attorneys – can damage Soleno’s reputation with investors and perhaps with prescribers. Regulatory scrutiny could also emerge: if the FDA or other regulators pick up on the safety reports or data integrity questions, they might initiate their own reviews. In sum, Soleno is facing significant external pressure from legal, investor, and possibly regulatory angles, all in the midst of trying to execute a complex drug launch.

Each of these risks underscores the fragile position Soleno is in. The company’s latest SEC filings even added cautions that new adverse event data being publicly released can “lead to a misinterpretation of safety signals…and a decrease in public confidence” in a drug (www.sec.gov) – a statement that seems to directly address the Scorpion-caused turmoil. For investors, it’s critical to monitor how (and if) Soleno’s management addresses these red flags. Transparency about post-market safety findings, maintaining physician trust, and delivering on commercial promises are all crucial to restoring confidence. Without clear progress on these fronts, SLNO will likely remain under a cloud of uncertainty.

Open Questions for Investors

Given the dynamic situation surrounding SLNO, several open questions remain unanswered. These will be key factors determining the company’s trajectory and whether shareholders ultimately see reward or further risk:

– Will VYKAT XR’s safety profile hold up under wider use? Both investors and regulators will be watching post-marketing data closely. An open question is whether the reported cardiac events are isolated cases or an inherent risk of the drug. Soleno’s commentary on FAERS data suggests uncertainty (www.sec.gov). If ongoing surveillance finds no alarming pattern, confidence in VYKAT XR could rebound. But if further safety signals emerge (or the FDA requires new warnings/monitoring), it could severely limit the drug’s adoption or even force a withdrawal. This question is paramount: the future of SLNO hinges on VYKAT XR remaining a safe therapy for PWS patients.

– Can the strong early sales momentum be sustained? Soleno impressed with its initial launch metrics (nearly $99 M in sales in 6 months) and broad insurance coverage (>100 M lives) (investors.soleno.life). However, the durability of this growth is in question. Will new patient starts continue at a high rate each quarter, or did pent-up demand from early adopters flatter the first numbers? It’s unclear how much of the addressable PWS population has already been reached versus still untapped. Additionally, physician sentiment could shift in light of the safety debate – some doctors may pause prescribing until there’s more clarity. Investors should ask whether VYKAT XR can keep expanding to new patients and younger age groups, or if uptake will plateau or decline if confidence wavers.

– What is the path forward in Europe and beyond? Soleno submitted a Marketing Authorization Application (MAA) in Europe in May 2025 to seek approval for DCCR (VYKAT XR) in PWS (investors.soleno.life). The outcome and timing of EU approval remains an open question. European regulators might scrutinize the drug’s risk/benefit profile stringently given the U.S. safety controversy. Will the EMA delay or add conditions to approval? And if approved, can Soleno effectively commercialize in Europe on its own? The company has substantial cash, but launching in Europe might require partnerships or significant investment. Beyond Europe, are there other markets (e.g. Japan or other regions) being targeted? The global expansion strategy and its success are uncertain at this stage, yet they represent potential upside (or additional risk/cost) for SLNO.

– How will Soleno deploy its large cash reserves? With over half a billion dollars raised, Soleno has the capital to do more than just market VYKAT XR. Management indicated the funds may go toward EU commercialization and “further R&D efforts, as well as general corporate purposes, which may include…acquisitions of complementary products or technologies” (investors.soleno.life). An open question is whether Soleno will pursue acquisitions or pipeline expansion to diversify its portfolio. Investors likely would welcome a smart bolt-on acquisition or development of a second drug (for PWS or another rare disease) to reduce reliance on VYKAT XR. On the other hand, any such move must be executed carefully – the company’s core expertise and focus have been on DCCR/PWS, so branching out carries integration and development risk. How effectively Soleno uses its cash hoard – whether to bolster VYKAT’s rollout, win approval in new markets, or buy new assets – will significantly influence its long-term value.

– What will be the outcome of shareholder investigations or potential lawsuits? The probes by Rosen Law and Hagens Berman raise uncertainty about possible legal action. An open question is if a securities class-action lawsuit will be filed (a common outcome when stock drops follow allegations of misleading statements). If so, how might Soleno resolve it – through a court fight, a settlement, or perhaps changes in corporate governance? While such legal matters can take years, any developments (like a class certification or preliminary findings) could impact the stock. Additionally, will Soleno’s management take steps to proactively improve transparency to placate investors? For example, they might start disclosing more frequent safety updates or hold investor calls addressing the short-seller claims. Rebuilding trust is critical at this juncture. How management and the board navigate the legal and reputational fallout remains an open question that could affect investor sentiment for some time.

– Is SLNO undervalued or overvalued at this point? Finally, investors are left to ponder the fundamental question: after the steep decline from its highs, does Soleno’s stock now present an attractive risk-reward, or do the risks still outweigh the potential? Bulls can point to the analyst consensus price target of ~$118 – over double the current price – suggesting significant upside if Soleno executes well (financhill.com). Bears, however, will note that such targets may not yet reflect the latest safety scare. The truth may depend on answers to all of the above questions. If VYKAT XR’s issues prove manageable and sales continue climbing, SLNO could indeed be a bargain at current levels. If not, further downside is possible. The divergence of opinions on SLNO is stark, and it encapsulates the uncertainty of investing in a single-product biotech. Only time (and data) will tell which thesis is correct.

In conclusion, Soleno Therapeutics has reached a pivotal moment. The company achieved a breakthrough for the PWS community by bringing VYKAT XR to market, unlocking significant revenue potential and hope for patients (investors.soleno.life). Yet that achievement is now guarded by clouds of concern – about safety, sustainability, and credibility. Investors are urged to stay extremely informed and, if they have significant exposure, perhaps to indeed “secure counsel” or expert advice in interpreting the evolving situation. The coming quarters should provide clarity on whether Soleno can dispel the red flags and justify the faith that many (including Wall Street analysts) have placed in its future (financhill.com), or whether the skeptics’ warnings will prove prescient. For now, SLNO remains a high-risk, high-reward story, and acting (or not acting) will depend on each investor’s risk tolerance and confidence in the answers to these critical open questions.

(investors.soleno.life) (portal.sina.com.hk) (www.prnewswire.com) (ng.investing.com) (www.prnewswire.com)

For informational purposes only; not investment advice.